Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Adenocarcinoma × Morphine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 14 Pain 10 Cancer Pain 10 Pain, Postoperative 9 Chronic Pain 6 Colonic Neoplasms 4 Agnosia 4 Mucositis 3 Lung Neoplasms 3 Colorectal Neoplasms 3 Breast Neoplasms 3 Supratentorial Neoplasms 2 Pancreatic Neoplasms 2 Pain, Intractable 2 Neoplastic Cells, Circulating 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Leukemia, Biphenotypic, Acute 2 Leukemia 2 Ileus 2 Wounds and Injuries 1 Waldenstrom Macroglobulinemia 1 Vesico-Ureteral Reflux 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Ulcer 1 Thrombocythemia, Essential 1

Interventions

Oxaliplatin 31 Fluorouracil 23 Gemcitabine 19 Leucovorin 18 Docetaxel 18 pembrolizumab 17 Capecitabine 15 Radiotherapy 13 Irinotecan 13 Bevacizumab 11 Cisplatin 10 Nivolumab 8 130-nm albumin-bound paclitaxel 8 Cyclophosphamide 7 Trastuzumab 6 Radiosurgery 6 Paclitaxel 6 Albumin-Bound Paclitaxel 6 S 1 (combination) 5 Metformin 5 Erlotinib Hydrochloride 5 Carboplatin 5 Blood Specimen Collection 5 Taxes 4 Sunitinib 4 Sorafenib 4 Pemetrexed 4 Esophagectomy 4 Chemoradiotherapy 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05325164 2022-12-05

METHADOPT

Ottawa Hospital Research Institute

Phase 3 Withdrawn

Cancer Pain, Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡